Legend Biotech logo

Legend Biotech

LEGN | NASDAQ
Chart Builder DCF Calculator
$15.99
-$1.51 (-8.63%)
At close: Nov 16, 2026, 4:00 PM ET
$16.10
+$0.11 (+0.69%)
After-hours: Nov 16, 2026, 7:52 PM ET
-8.63%

Rating

Updated: Nov 16, 2026
44.7
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #400/1021 (Top 39%)

Key Statistics

Market Data

Market Cap $2.96B
1D Range
15.97 17.49
52W Range
15.97 36.28

Valuation (TTM)

PE -533
PB 2.32
EV/EBITDA 22.82

Valuation (NTM)

Forward PE 218.75
Forward PEG 15.86
Price Target $65.00
Loading financial charts...

Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other ind...

Sector Healthcare
Industry Biotechnology
Employees 3,200
IPO Date Jun 5, 2020
Fiscal Year January - December

Latest News

Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript

6 days ago · seekingalpha.com

Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript
What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

6 days ago · marketbeat.com

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call
Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights

6 days ago · globenewswire.com

Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average

19 days ago · zacks.com

Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors

21 days ago · zacks.com

Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

21 days ago · globenewswire.com

Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive

26 days ago · seekingalpha.com

Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

2 months ago · globenewswire.com

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

2 months ago · globenewswire.com

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

2 months ago · globenewswire.com

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

Earnings

Latest Earnings
Nov 10, 2026
EPS
$0.14
Beat +1300.00%
REV
$359.5M
Miss -0.54%
Next Earnings
Mar 9, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$65.00
Upside
+306.50%
Buy (5)
Hold (4)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.